Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 14/20 | 0.39 |
| ▸ | RAMP1 | O60894 | 6/20 | 0.39 |
| ▸ | ADM2 | Q7Z4H4 | 4/20 | 0.35 |
| ▸ | CALCA | P06881 | 2/20 | 0.34 |
| ▸ | CALCB | P10092 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935911 | 0.84 | CALCRL (0.39) | CALCRLRAMP1ADM2CALCACALCB | |
| SCHEMBL24220811 | 0.81 | CALCRL (0.54) | CALCRLRAMP1ADM2CALCACALCB | |
| SCHEMBL13062458 | 0.81 | CALCRL (0.54) | CALCRLRAMP1ADM2CALCACALCB | |
| SCHEMBL261125 | 0.81 | CALCRL (0.36) | CALCRLRAMP1ADM2CALCACALCB | |
| SCHEMBL13015182 | 0.81 | CALCRL (0.38) | CALCRLRAMP1ADM2CALCB | |
| SCHEMBL13062460 | 0.80 | PARP1 (0.32) | — | |
| SCHEMBL7031017 | 0.80 | CALCRL (0.43) | CALCRLRAMP1ADM2CALCB | |
| SCHEMBL13062457 | 0.79 | CALCRL (0.40) | CALCRLRAMP1ADM2CALCACALCB | |
| SCHEMBL10119963 | 0.78 | CALCRL (0.44) | CALCRLRAMP1ADM2 | |
| SCHEMBL18307248 | 0.77 | CALCRL (0.39) | CALCRLRAMP1ADM2CALCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | CALCRL 3/4885RAMP1 53/4885ADM2 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.